TCID

• Description :

  TCID (4,5,6,7-Tetrachloroindan-1,3-dione) is a potent and selective neuronal ubiquitin C-terminal hydrolase (UCH-L3) inhibitor with an IC50 of 0.6 μM[1]. TCID diminishes glycine transporter GlyT2 ubiquitination in brainstem and spinal cord primary neurons[2].

• Product Name Alternative :

  4,5,6,7-Tetrachloroindan-1,3-dione

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H312, H332

• Target :

  Deubiquitinase

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/tcid.html

• Purity :

  99.78

• Solubility :

  DMSO : 20 mg/mL (ultrasonic)

• Smiles :

  O=C1CC(C2=C1C(Cl)=C(Cl)C(Cl)=C2Cl)=O

• Molecular Formula :

  C9H2Cl4O2

• Molecular Weight :

  283.92

• Precautions :

  H302, H312, H332

• References & Citations :

  [1]Liu Y, et al. Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cellline. Chem Biol. 2003 Sep;10 (9) :837-46.|[2]de Juan-Sanz J, et al. Constitutive endocytosis and turnover of the neuronal glycine transporter GlyT2 is dependent on ubiquitination of a C-terminal lysine cluster. PLoS One. 2013;8 (3) :e58863.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [30675-13-9]